Compare Liberty Global Ltd Class C (LBTYK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Neurocrine Biosciences Inc — how do they compare? Liberty Global Ltd Class C trades at $9.98 (market cap $3.48B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.8× Liberty Global Ltd Class C's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| LBTYK | NBIX | |
|---|---|---|
Market Cap | $3.48B | $16.76B |
Sector | Technology | Health |
52-Week High | $12.67 | $185.50 |
52-Week Low | $9.59 | $123.10 |
Enterprise Value | $10.13B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $10.24, down 2.38% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for a 2027 Ziggo Group listing, a key strategic move.
Despite deep losses, the stock appears undervalued on price-to-sales (0.7) and price-to-book (0.37) metrics. Analyst sentiment is strongly bullish (69% buy ratings), seeing upside from asset monetization and the Ziggo spin-off. Key risks include persistent negative margins and execution of the separation plan.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
